Add to Book Shelf
Flag as Inappropriate
Email this Book

Crs Report for Congress Received through the Crs Web Vaccine Policy Issues Updated May 19, 2005

By Thaul, Susan

Click here to view

Book Id: WPLBN0000009134
Format Type: PDF eBook:
File Size: 0.1 MB
Reproduction Date: 2008

Title: Crs Report for Congress Received through the Crs Web Vaccine Policy Issues Updated May 19, 2005  
Author: Thaul, Susan
Volume:
Language: English
Subject: Government publications, Legislation., Government Printing Office (U.S.)
Collections: Government Library Collection
Historic
Publication Date:
Publisher: Government Printing Office

Citation

APA MLA Chicago

Thaul, B. S. (n.d.). Crs Report for Congress Received through the Crs Web Vaccine Policy Issues Updated May 19, 2005. Retrieved from http://gutenberg.cc/


Excerpt
Summary: This report’s focus is on vaccination, one of the most cost-effective methods available to prevent infectious diseases. Whether a vaccine’s target is naturally occurring or present because of hostile intent, the issues policy makers must deal with include vaccine development, production, availability, safety, effectiveness, and access. Vaccines are biologics: their basic components begin as living material. They introduce bacteria or dead or weakened viruses into a person or animal to stimulate an immune reaction that the body will remember if assaulted by the same pathogen in the future.

Table of Contents
Contents Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 What Is A Vaccine? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Procedures for the Approval and Regulation of Biololgics . . . . . . . . . . . . . . 2 Stakeholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Laws Approved by the 107th Congress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Legislative Activity in the 108th Congress . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Continuing Legislative Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Availability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Problems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Production Costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Production Failures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Market . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Planning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Possible Legislative Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Financial Incentives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Partnerships . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Improved Coordination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Ensuring Safety and Effectiveness May Delay Availability . . . . . . . . 11 Safety and Effectiveness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Problems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Side-Effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Insufficient Knowledge and Inadequate Risk Communication . . . . . . 15 Assessment of Competing Products . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Production of Generic Biologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Possible Legislative Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Improving Post-Licensure Adverse-Event Surveillance . . . . . . . . . . . 16 Education and Risk Communication . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Studies in Pharmacoepidemiology and Pharmacoeconomics . . . . . . . 17 Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Problems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Possible Legislative Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Coordination of Government Financing Programs . . . . . . . . . . . . . . . 19 Payment for Vaccination and Follow-Up Care . . . . . . . . . . . . . . . . . . 20 Global Health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

 
 



Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.